期刊文献+

应用量表研究86例帕金森病患者睡眠障碍及与其生活质量的关系 被引量:5

The relationship between sleep disorder and the quality of life in 86 patients with Parkinson's disease
下载PDF
导出
摘要 目的分析帕金森病(PD)患者睡眠障碍的临床特点及其与生活质量水平之间的关系。方法应用帕金森病睡眠量表(PDSS)和帕金森病生活质量调查表(PDQ39)对86例PD患者的睡眠情况和临床特征进行量表调查,并将PD患者PDQ39结果与其睡眠情况做描述性相关性研究。结果PD患者中出现睡眠障碍者79例(91.86%),主要是睡眠破碎(75.6%)和日间过度嗜睡(74.4%),其严重程度与生活质量呈负相关(P〈0.05)。结论PD患者睡眠障碍以睡眠破碎和日间过度嗜睡发生率最高,其程度越重,则生活质量越差。 ObjectiveTo analyze the clinical features of sleep disorder in Parkinson’s disease patients and their association with the quality of life. MethodsThe sleep-related problems, clinical features, and quality of life of 86 Parkinson’s disease patients were analyzed using the Parkinson Disease Sleep Scale (PDSS) and the 39-item Parkinson′s Disease Questionnaire (PDQ39). The relationship between the results of PDSS and PDQ39 was analyzed using the descriptive correlation study. ResultsThe incidence of sleep disorder was 91.86% (79 patients), where fragmented sleep (75.6%) and EDS (74.4%) were the most common problems. The severity of sleep disorder was negatively correlated with the quality of life (P〈0.05). ConclusionsThe incidence of fragmented sleep and EDS are the highest in Parkinson’s disease patients with sleep disorder. The severity of sleep disorder is directly correlated with the diminishing of quality of life.
出处 《徐州医科大学学报》 CAS 2017年第11期751-753,共3页 Journal of Xuzhou Medical University
基金 国家自然科学基金(81671269)
关键词 帕金森病 帕金森病睡眠量表 帕金森病生活质量调查表 Parkinson's disease Parkinson Disease Sleep Scale the 39 -item Parkinsong Disease Questionnaire
  • 相关文献

参考文献1

二级参考文献16

  • 1Parkinson Study Group.Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.N Engl J Med,1993,328:176-183. 被引量:1
  • 2Riederer P,Lachenmayer L.Selegiline's neuroprotective capacity revisited.J Neural Transm,2003,110:1273-1278. 被引量:1
  • 3Shults CW,Oakes D,Kieburtz K,et al.Effects of coenzyme Q10 in early Parkinson disease:evidence of slowing of the functional decline.Arch Neurol,2002,59:1541-1550. 被引量:1
  • 4Albin RL,Frey KA.Initial agonist treatment of Parkinson disease.Neurology,2003,60:390-394. 被引量:1
  • 5Olanow W,Schapira AH,Rascol O.Continuous dopamine-receptor stimulation in early Parkinson's disease.Trends Neurosci,2000,23(10 Suppl):S117-S126. 被引量:1
  • 6Olanow CW,Watts RL,Koller WC.An algorithm (decision tree)for the management of Parkinson's disease (2001):treatment guidelines.Neurology,2001,56(11 Suppl 5):S1-S88. 被引量:1
  • 7Junghanns S,Glockler T,Reichmann H.Switching and combining of dopamine agonists.Neurol,2004,251 Suppl 6:VI/19-23. 被引量:1
  • 8Olanow CW,Stocchi F.COMT inhibitors in Parkinson's disease can they prevent and/or reverse levodopa-induced motor complications?Neurology,2004,62 Suppl 1:S72-S81. 被引量:1
  • 9Waters C.Other pharmacological treatments for motor complications and dyskinesias.Mov Disord,2005,20 Suppl Ⅱ:S38-S44. 被引量:1
  • 10Shiraishi M,Kamo T,Hotta M,et al.Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.J Neural Transm,2004,111:725-732. 被引量:1

共引文献101

同被引文献42

引证文献5

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部